Results 71 to 80 of about 174,454 (241)

Identification Epitope on VP4 Protein of Senecavirus A Recognized by a Monoclonal Antibody

open access: yesAnimal Research and One Health, EarlyView.
This study aims to identify conserved antigenic epitopes on the SVA VP4 protein using monoclonal antibodies, providing valuable tools for further exploring its functions and developing detection methods. SVA VP4 protein was expressed in Escherichia coli and purified with High‐Affinity Ni‐Charged Resin FF.
Liang Meng   +7 more
wiley   +1 more source

Investigating the Heat Stability and Inactivation Conditions of Decapod Iridescent Virus 1 (DIV1)

open access: yesAnimal Research and One Health, EarlyView.
Heat treatment effectively inactivates decapod iridescent virus 1 (DIV1) under milder conditions than current WOAH recommendations. DIV1 infectivity was eliminated at 56°C for 30 min, 60°C for 15 min, or 70°C for 1 min, providing optimized heat treatment strategies for aquaculture biosecurity and seafood safety.
Yonghui Feng   +4 more
wiley   +1 more source

Adaptive Machine Learning Framework for Optimizing the Affinity Purification of Adeno‐Associated Viral Vectors

open access: yesBiotechnology and Bioengineering, EarlyView.
ABSTRACT Adeno‐associated viral (AAV) vectors for gene therapy are becoming integral to modern medicine, providing therapeutic options for diseases once deemed incurable. Currently, viral vector purification is a critical bottleneck in the gene therapy industry, impacting product efficacy and safety as well as accessibility and cost to patients ...
Kelvin P. Idanwekhai   +9 more
wiley   +1 more source

Performance of large virus removal filters during AAV processing: Influence of flux and process disruptions

open access: yesBiotechnology Progress, EarlyView.
Abstract As adeno‐associated viral vectors (AAV) continue to advance through the clinical pipeline, effective downstream purification strategies must be developed to ensure bulk drug purity and safety. AAV are produced within mammalian cells, bringing forth risks associated with viral contamination.
Akshay S. Chaubal   +5 more
wiley   +1 more source

A NEW CAPSID [PDF]

open access: yesThe Canadian Entomologist, 1903
Lygus Chagnoni, n. sp.— This species of the genus Lygus is of a form near to L. pabulinus, Linn., in appearance.It is ovate, convex bright green in living specimens, with irregular purplish-brown markings at the base of the membrane, smooth and without bristles, and a silky pubesecence on the sides of the pronotum, which has an orange-yellow border ...
openaire   +1 more source

Sequential, chromosome‐specific glutamine synthetase double knockout with Cas‐CLOVER establishes enhanced CHO platforms for cell line development

open access: yesBiotechnology Progress, EarlyView.
This study established the first creation of a commercially available double GS knockout (DKO) from a single KO in CHO‐K1 cells, called CleanCut GS CHO using Cas‐CLOVER. When combined with the Harbor‐IN transposase system, CleanCut GS CHO cells demonstrated a highly antibody productivity.
Cintia Gomez Limia   +7 more
wiley   +1 more source

Advancing Maternal Health with Long‐Acting Therapeutics: Priorities, Efficacy and Safety Considerations, and Emerging Technologies

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Maternal health remains a critical global concern, particularly in underserved populations and in low‐ and middle‐income countries where access to safe and effective therapeutics is limited. Despite the use of medications by most women during pregnancy, the exclusion of pregnant and lactating women from clinical trials has resulted in significant data ...
Rachel K. Scott   +7 more
wiley   +1 more source

Antibody Competition Reveals Surface Location of HPV L2 Minor Capsid Protein Residues 17–36

open access: yesViruses, 2017
The currently available nonavalent human papillomavirus (HPV) vaccine exploits the highly antigenic L1 major capsid protein to promote high-titer neutralizing antibodies, but is limited to the HPV types included in the vaccine since the responses are ...
Stephanie M. Bywaters   +5 more
doaj   +1 more source

Clinical Pharmacology Quality Assurance Program for Global HIV and Co‐Infection Drug Development

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
When the acquired immunodeficiency syndrome emerged in the 1980s, the United States National Institutes of Health established research networks to conduct clinical trials with the pharmaceutical industry to identify effective antiretroviral therapeutics.
Robin DiFrancesco   +17 more
wiley   +1 more source

Recombinant in vitro assembled hepatitis C virus core particles induce strong specific immunity enhanced by formulation with an oil-based adjuvant

open access: yesBiological Research, 2009
In the present work, immunogenicity of recombinant in vitro assembled hepatitis C virus core particles, HCcAg.120-VLPs, either alone or in combination with different adjuvants was evaluated in BALB/c mice. HCcAg.120-VLPs induced high titers of anti-HCcAg.
NELSON ACOSTA-RIVERO   +15 more
doaj  

Home - About - Disclaimer - Privacy